Article
Oncology
Maximilian O. Schaettler, Rupen Desai, Anthony Z. Wang, Alexandra J. Livingstone, Dale K. Kobayashi, Andrew T. Coxon, Jay A. Bowman-Kirigin, Connor J. Liu, Mao Li, Diane E. Bender, Michael J. White, David M. Kranz, Tanner M. Johanns, Gavin P. Dunn
Summary: Researchers isolated a TCR specific for the Imp3(D81N) neoantigen and generated the MISTIC mouse model. Adoptive cellular therapy using MISTIC T cells showed potential therapeutic efficacy for glioblastoma treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Vid Leko, Gal Cafri, Rami Yossef, Biman Paria, Victoria Hill, Devikala Gurusamy, Zhili Zheng, Jared J. Gartner, Todd D. Prickett, Stephanie L. Goff, Paul Robbins, Yong-Chen Lu, Steven A. Rosenberg
Summary: By stimulating patient blood-derived memory T cells in vitro, researchers found that in a cohort of five patients with glioblastoma, circulating CD4(+) memory T cells from one patient specifically recognized a cancer neoantigen harboring a mutation in the EED gene that was unique to that patient's tumor. This finding suggests the potential for isolating neoantigen-reactive T cells from patients with glioblastoma and further developing neoantigen-directed adoptive T cell therapy for this disease.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Kirit Singh, Kelly M. Hotchkiss, Aditya A. Mohan, Jessica L. Reedy, John H. Sampson, Mustafa Khasraw
Summary: Glioblastoma is the most common primary brain tumor in adults with a uniformly lethal prognosis. While immunotherapies have not shown significant clinical benefit in treatment, bispecific T-cell engagers are promising antibody fragment therapies. However, the challenges posed by the tumor microenvironment, immune privilege, and blood-brain barrier suggest that a single agent approach may be insufficient for lasting antitumor efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Saad M. Khan, Rupen Desai, Andrew Coxon, Alexandra Livingstone, Gavin P. Dunn, Allegra Petti, Tanner M. Johanns
Summary: Dysfunctional CD4 T cells are associated with terminal CD8 T-cell exhaustion in glioblastoma, influencing the efficacy of PD-1 blockade. Adding a CD40 agonist to PD-1 blockade therapy improves survival rates in glioblastoma, suggesting a potential synergistic immunotherapeutic approach.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Johnny Duerinck, Julia Katharina Schwarze, Gil Awada, Jens Tijtgat, Freya Vaeyens, Cleo Bertels, Wietse Geens, Samuel Klein, Laura Seynaeve, Louise Cras, Nicky D'Haene, Alex Michotte, Ben Caljon, Isabelle Salmon, Michael Bruneau, Mark Kockx, Sonia Van Dooren, Anne-Marie Vanbinst, Hendrik Everaert, Ramses Forsyth, Bart Neyns
Summary: In this phase I clinical trial, intracerebral administration of NIVO and IPI following maximal safe resection of recurrent glioblastoma was found to be feasible, safe, and associated with encouraging overall survival outcomes when compared to historical cohorts. No significant difference was found in terms of progression-free survival.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Takayuki Ohkuri, Akemi Kosaka, Maki Ikeura, Andres M. Salazar, Hideho Okada
Summary: While adoptive transfer of T-cells has been successful for B cell malignancies, developing effective T-cell-based immunotherapy for CNS tumors like glioblastoma remains challenging. Tc17-1 cells, which produce both IL-17 and IFN-gamma, showed promising results in combination with poly-ICLC and peptide vaccine treatment in a preclinical GBM model.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Kirit Singh, Kelly M. Hotchkiss, Kisha K. Patel, Daniel S. Wilkinson, Aditya A. Mohan, Sarah L. Cook, John H. Sampson
Summary: Glioblastoma is an immunologically 'cold' tumor characterized by low or absent numbers of tumor-infiltrating lymphocytes, which if present are exhausted and ineffective. To maximize immunotherapy efficacy in glioblastoma, it is highly desirable to enhance the trafficking of lymphocytes to the tumor. However, the process of T cell recruitment into the central nervous system is tightly regulated, involving multiple steps including interaction with the blood-brain barrier and navigating the tumor microenvironment.
Article
Oncology
Brie Chun, Joanna Pucilowska, ShuChing Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L. Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul A. Fields, Valerie Conrad, Mark Schmidt, Walter J. Urba, Alison K. Conlin, Heather L. McArthur, David B. Page
Summary: This study investigates the effects of pembrolizumab combined with paclitaxel or capecitabine on T-cell subsets in triple-negative breast cancer patients. The results show that these treatments result in similar lymphodepletions across peripheral T-cell subsets and do not alter T-cell clonal diversity. The findings contribute to our understanding of the impact of chemoimmunotherapy on the immune system.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Pharmacology & Pharmacy
Vignesh Kamath
Summary: Two decades ago, cancer vaccines were hailed as a breakthrough in cancer treatment, but failed to show significant improvements in clinical trials. Cancer cell resistance to immune response is identified as a major obstacle. The review discusses different types of cancer vaccines, design strategies, and potential therapies to address the limitations of cancer vaccine treatments.
DRUG DISCOVERY TODAY
(2021)
Article
Chemistry, Multidisciplinary
Yanan Gao, Qingyu Zhao, Huiling Dong, Min Xiao, Xuefei Huang, Xuanjun Wu
Summary: Cytotoxic T-lymphocytes (CTLs) play a central role in protective immunity against malignancies and infectious diseases. This study developed partially oxidized acetalated dextran nanoparticles (Ox-AcDEX NPs) as a general vaccine delivery platform. By conjugating CTL peptide epitopes and immune-enhancing adjuvants, effective vaccines against cancer and viruses were successfully created, demonstrating the potential for immune protection.
ADVANCED FUNCTIONAL MATERIALS
(2021)
Article
Oncology
Kevin Dang, Giulia Castello, Starlynn C. Clarke, Yuping Li, Aarti Balasubramani, Andrew Boudreau, Laura Davison, Katherine E. Harris, Duy Pham, Preethi Sankaran, Harshad S. Ugamraj, Rong Deng, Serena Kwek, Alec Starzinski, Suhasini Iyer, Wim van Schooten, Ute Schellenberger, Wenchao Sun, Nathan D. Trinklein, Roland Buelow, Ben Buelow, Lawrence Fong, Pranjali Dalvi
Summary: TNB-585, an anti-CD3xPSMA TCE, shows promising efficacy in vitro in inducing activation and proliferation of human T cells, killing PSMA(+) prostate tumor cells, and reducing cytokine release and regulatory T cell activation. In addition, TNB-585 demonstrates potent efficacy against patient-derived prostate tumors ex vivo and in vivo, suggesting it may be a promising therapy for mCRPC with lower incidence and severity of CRS compared to TCEs with high-affinity anti-CD3 domains.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Karen Kai-Lin Fang, Jongbok Lee, Ismat Khatri, Yoosu Na, Li Zhang
Summary: The use of allogeneic CAR4-DNTs as adoptive cell therapy for T-cell malignancies is effective. CAR4-DNTs can effectively target T-ALL and PTCL and have superior cytotoxicity compared to empty-vector transduced DNTs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Jara Palomero, Carla Panisello, Maria Lozano-Rabella, Ricky Tirtakasuma, Judit Diaz-Gomez, Daniela Grases, Helena Pasamar, Laura Arregui, Eduard Dorca Duch, Esther Guerra Fernandez, Ana Vivancos, Carlos E. de Andrea, Ignacio Melero, Jordi Ponce, August Vidal, Josep Maria Piulats, Xavier Matias-Guiu, Alena Gros
Summary: Our study investigates the prevalence, phenotype, specificity and prognostic value of tumor infiltrating lymphocytes (TILs) in endometrial cancer (EC). We found that CD8(+)TILs expressing high levels of PD-1 and CD39 were associated with tumor reactivity and improved patient survival. The co-expression of inhibitory and activation markers on PD-1(hi) CD4(+) T cells was also observed, which accumulated antitumor T cells and correlated with prolonged survival in EC patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Qiaoqi Sui, Dingxin Liu, Wu Jiang, Jinghua Tang, Lingheng Kong, Kai Han, Leen Liao, Yuan Li, Qingjian Ou, Binyi Xiao, Guochen Liu, Yihong Ling, Jiewei Chen, Zexian Liu, Zhixiang Zuo, Zhizhong Pan, Penghui Zhou, Jian Zheng, Pei-Rong Ding
Summary: DKK1 suppresses the antitumor immune reaction via the GSK3 beta/E2F1/T-bet axis in CD8+ T cells. Elevated serum DKK1 predicts poor tumor response to PD-1 blockade in dMMR/MSI CRCs, and DKK1 neutralization may restore sensitivity to PD-1 blockade.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Eunhee Lee, Shinai Lee, Sumyeong Park, Yong-Gyu Son, Jiseon Yoo, Youngil Koh, Dong-Yeop Shin, Yangmi Lim, Jonghwa Won
Summary: A novel IgG-based asymmetric bispecific antibody ABL602 2+1, targeting CLL-1 and CD3, showed potent tumor-killing activity and reduced cytokine release, making it a promising candidate for treating patients with AML.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Catherine Flores, Gavin Dunn, Peter Fecci, Michael Lim, Duane Mitchell, David A. Reardon
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2022)
Article
Multidisciplinary Sciences
Yaoying Wu, Hanning Wen, Zachary J. Bernstein, Kelly M. Hainline, Tykia S. Blakney, Kendra L. Congdon, David J. Snyder, John H. Sampson, Luis Sanchez-Perez, Joel H. Collier
Summary: The study demonstrates the potential clinical benefit of vaccine-induced antibody responses for tumor treatments when combined with simultaneous CD8(+) and CD4(+) responses, using a nanofiber vaccine design approach. Additionally, the study highlights the importance of supramolecular nanomaterials in developing multiepitope cancer vaccines.
Article
Oncology
Andrew T. Fairchild, Joseph K. Salama, Walter F. Wiggins, Bradley G. Ackerson, Peter E. Fecci, John P. Kirkpatrick, Scott R. Floyd, Devon J. Godfrey
Summary: The purpose of this study was to develop a computer-aided detection (CAD) system that enhances human performance, especially in identifying small inconspicuous brain metastases. This was achieved by training a convolutional neural network on a unique magnetic resonance imaging (MRI) dataset containing subtle brain metastases that were not detected prospectively during routine clinical care.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Clinical Neurology
Aden P. P. Haskell-Mendoza, Ethan S. S. Srinivasan, Emily C. C. Lerner, Ryan M. M. Edwards, Allison M. M. Schwalb, Joshua D. D. Jackson, Andrew A. A. Hardigan, Eugene J. J. Vaios, Peter E. E. Fecci
Summary: LITT is a novel treatment for brain tumors using photocoagulation with a stereotactically implanted laser fiber. This study aims to quantify the risk of tumor seeding along the laser fiber tract in patients receiving LITT for primary or metastatic brain tumors at a high-volume treatment center.
Article
Oncology
David J. Carpenter, Andrew T. Fairchild, Justus D. Adamson, Peter E. Fecci, John H. Sampson, James E. Herndon II, Jordan A. Torok, Trey C. Mullikin, Grace J. Kim, Zachary J. Reitman, John P. Kirkpatrick, Scott R. Floyd
Summary: HF-SRS is a preferred treatment for larger or symptomatic brain metastases. This study examined clinical outcomes and predictive factors of patients undergoing HF-SRS with or without surgical resection. Results showed that patients with resected brain metastases had higher overall survival, but there were risks of local progression and distant brain progression.
ADVANCES IN RADIATION ONCOLOGY
(2023)
Correction
Oncology
Emily Claire Lerner, Ethan S. Srinivasan, Gloria Broadwater, Aden P. Haskell-Mendoza, Eugene J. Vaios, Ryan M. Edwards, Lucas P. Wachsmuth, David Huie, Scott R. Floyd, Justus D. Adamson, Peter E. Fecci
ADVANCES IN RADIATION ONCOLOGY
(2023)
Article
Neurosciences
B. Saatian, K. Deshpande, R. Herrera, S. Sedighi, R. Eisenbarth, M. Iyer, D. Das, A. Julian, V. Martirosian, A. Lowman, P. LaViolette, J. Remsik, A. Boire, E. Sankey, P. E. Fecci, M. S. Shiroishi, F. Chow, K. Hurth, J. Neman
Summary: This study investigates the impact of chemotherapy on breast-to-brain metastasis and the promotion of tumor-driven neurofibrillary tangles. The results show that chemotherapy increases brain-barrier permeability and facilitates tumor infiltration. Chemotherapy also contributes to the formation of neurofibrillary tangles that destabilize the brain barrier.
JOURNAL OF NEUROSCIENCE RESEARCH
(2023)
Editorial Material
Biochemistry & Molecular Biology
Kirit Singh, Kelly M. Hotchkiss, Ian F. Parney, John De Groot, Solmaz Sahebjam, Nader Sanai, Michael Platten, Evanthia Galanis, Michael Lim, Patrick Y. Wen, Giuseppe Minniti, Howard Colman, Timothy F. Cloughesy, Minesh P. Mehta, Marjolein Geurts, Isabel Arrillaga-Romany, Annick Desjardins, Kirk Tanner, Susan Short, David Arons, Elizabeth Duke, Wolfgang Wick, Stephen J. Bagley, David M. Ashley, Priya Kumthekar, Roel Verhaak, Anthony J. Chalmers, Anoop P. Patel, Colin Watts, Peter E. Fecci, Tracy T. Batchelor, Michael Weller, Michael A. Vogelbaum, Matthias Preusser, Mitchel S. Berger, Mustafa Khasraw
Summary: A breakthrough in drug discovery for glioblastoma necessitates the consecutive collection of central nervous system tissue through window of opportunity trials.
Article
Oncology
Emily C. C. Lerner, Karolina I. I. Woroniecka, Vincent M. M. D'Anniballe, Daniel S. S. Wilkinson, Aditya A. A. Mohan, Selena J. J. Lorrey, Jessica Waibl-Polania, Lucas P. P. Wachsmuth, Alexandra M. M. Miggelbrink, Joshua D. D. Jackson, Xiuyu Cui, Jude A. A. Raj, William H. H. Tomaszewski, Sarah L. L. Cook, John H. H. Sampson, Anoop P. P. Patel, Mustafa Khasraw, Michael D. D. Gunn, Peter E. E. Fecci
Summary: The traditional concept of tumor immune escape through MHC-I downregulation is challenged by the finding that CD8(+) T cells can kill tumor cells lacking MHC-I expression. This killing is mediated by the interaction between T cell NKG2D and tumor NKG2D ligands, which are highly expressed on MHC-loss variants. The killing is antigen independent but requires prior T cell activation. These findings suggest that the NKG2D-NKG2DL axis is a potential therapeutic target for enhancing T cell-dependent anti-tumor immunity against MHC-loss variants.
Article
Oncology
Ethan S. Srinivasan, Yang Liu, Ren A. Odion, Pakawat Chongsathidkiet, Lucas P. Wachsmuth, Aden P. Haskell-Mendoza, Ryan M. Edwards, Aidan J. Canning, Gavin Willoughby, Joseph Hinton, Stephen J. Norton, Christopher D. Lascola, Paolo F. Maccarini, Christopher L. Mariani, Tuan Vo-Dinh, Peter E. Fecci
Summary: This study demonstrates the use of plasmonics-active gold nanostars (GNS) to improve the efficiency and safety of laser interstitial thermal therapy (LITT). The results show that GNS can selectively accumulate within intracranial tumors and amplify the ablative effects of laser ablation. In vitro experiments also demonstrate increased rates of heating, contouring of heat to tumor borders, and decreased heating of surrounding regions when GNS is added.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Selena J. Lorrey, Jessica Waibl Polania, Lucas P. Wachsmuth, Alexandra Hoyt-Miggelbrink, Zachariah P. Tritz, Ryan Edwards, Delaney M. Wolf, Aaron J. Johnson, Peter E. Fecci, Katayoun Ayasoufi
Summary: The nervous and immune systems interact in a reciprocal manner, leading to systemic immune derangements across various CNS pathologies. These immune changes, including T-cell lymphopenia and sequestration within the bone marrow, have implications for the treatment and outcomes of neurologic pathologies.
NEURO-ONCOLOGY ADVANCES
(2023)
Meeting Abstract
Immunology
Daniel S. Wilkinson, Katherine Ryan, Joseph Wilson, Vidyalakshmi Chandramohan, Daniel Landi, Darell Bigner, Peter E. Fecci
JOURNAL OF IMMUNOLOGY
(2022)
Article
Oncology
John F. de Groot, Albert H. Kim, Sujit Prabhu, Ganesh Rao, Adrian W. Laxton, Peter E. Fecci, Barbara J. O'Brien, Andrew Sloan, Veronica Chiang, Stephen B. Tatter, Alireza M. Mohammadi, Dimitris G. Placantonakis, Roy E. Strowd, Clark Chen, Constantinos Hadjipanayis, Mustafa Khasraw, David Sun, David Piccioni, Kaylyn D. Sinicrope, Jian L. Campian, Sylvia C. Kurz, Brian Williams, Kris Smith, Zulma Tovar-Spinoza, Eric C. Leuthardt
Summary: Laser ablation is a viable treatment option for patients with new and recurrent glioblastoma, particularly for those with IDH wild-type newly diagnosed glioblastoma. Post-procedure radiation and chemotherapy can significantly improve survival.
NEURO-ONCOLOGY ADVANCES
(2022)
Article
Oncology
Matthew M. Grabowski, Ethan S. Srinivasan, Eugene J. Vaios, Eric W. Sankey, Balint Otvos, Daria Krivosheya, Alex Scott, Michael Olufawo, Jun Ma, Elena Fomchenko, James E. Herndon, Albert H. Kim, Veronica L. Chiang, Clark C. Chen, Eric C. Leuthardt, Gene H. Barnett, John P. Kirkpatrick, Alireza M. Mohammadi, Peter E. Fecci
Summary: A retrospective study found that LITT+SRT is more effective than LITT or repeat SRT alone in the treatment of recurrent brain metastasis after SRT failure. Prospective trials are needed to validate the efficacy of this combination therapy.
NEURO-ONCOLOGY ADVANCES
(2022)
Proceedings Paper
Engineering, Biomedical
Matthew Tucker, Matthew Lacayo, Suzanna Joseph, Weston Ross, Pakawat Chongsathidkiet, Peter Fecci, Patrick J. Codd
Summary: This study aims to determine the effectiveness of a novel non-contact tumor detection device in identifying metastatic melanoma boundaries in tissue-mimicking phantoms and ex vivo mouse brain tissue. The device successfully detected tumor boundaries and differences in fluorescence intensity between healthy and neoplastic tissue.
CLINICAL AND TRANSLATIONAL NEUROPHOTONICS 2022
(2022)
